Percutaneous Bcg Treatment in Superficial Transitional Cell Cancer of the Upper Urinary Tract

From January 1989 to September 1992, 5 patients (age 58–68 years) were treated with percutaneous Pasteur BCG for superficial transitional cell carcinoma of the upper urinary tract. In 4 cases BCG was prophylactic after endourological resection of the tumors. In one case of bilateral Tis of the upper urinary tract, BCG was administered for therapeutical purposes. Every patient received 375 mg Pasteur BCG in 250 ml saline, every 2 weeks for 6 consecutive weeks in 2 patients, 5 weeks in 1, and 4 in 2. No major complications were observed. After a median follow-up of 10.2 months, 4 patients are disease free, 1 patient underwent nephroureterectomy. Percutaneous BCG in upper tract superficial transitional cell cancer seems a feasible option in selected cases.

Download Full-text

Conservative Management of Transitional Cell Carcinoma of the Kidney and Ureter

Diagnostic and Therapeutic Endoscopy ◽

10.1155/dte.1.121 ◽

1995 ◽

Vol 1 (3) ◽

pp. 121-123 ◽

Cited By ~ 9

Author(s):

Gregory T. Bales ◽

Edward S. Lyon ◽

Glenn S. Gerber

Keyword(s):

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Cell Cancer ◽

Transitional Cell ◽

Disease Recurrence ◽

Upper Urinary Tract ◽

Multiple Organ ◽

Low Grade ◽

Transitional Cell Cancer ◽

Disease Free

We report six patients with upper tract transitional cell neoplasms who were treated by an endourologic approach. Two patients had undergone nephroureterectomy previously, whereas one patient had a single functioning kidney. Two patients were deemed candidates for endourologic procedures secondary to significant comorbid disease precluding major open surgery. The final patient had a low-grade distal ureteral lesion and desired a conservative approach.Of six patients, two were rendered tumor free without recurrence 48 months and 60 months after surgery. Two patients had multiple superficial recurrences managed endoscopically and are currently disease free after 12 and 48 months, respectively. One patient died from metastatic transitional cell cancer 18 months postoperatively whereas one died perioperatively secondary to bleeding and multiple organ failure.Of five patients who tolerated endoscopic therapy, four were disease free with a mean follow-up of 30 months. Endoscopic treatment of upper urinary tract transitional cell carcinoma is feasible, although the risk of disease recurrence and progression may be significant.

Download Full-text

Transitional cell carcinoma of the upper urinary tract: a puzzle

International Journal of Advances in Medicine ◽

10.18203/2349-3933.ijam20204078 ◽

2020 ◽

Vol 7 (10) ◽

pp. 1585

Author(s):

Soumish Sengupta ◽

Supriya Basu ◽

Kadambari Ghosh

Keyword(s):

Urinary Tract ◽

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Pelvis ◽

Transitional Cell ◽

Expectant Management ◽

Upper Urinary Tract ◽

Urinary Tuberculosis ◽

Gross Haematuria

Transitional cell carcinoma (TCC) of the upper urinary tract has a puzzling presentation. This is a case report of a 44 year old male with history for smoking 20 pack years presenting with cough, haemoptysis and microscopic haematuria. His sputum was positive for acid fast bacilli. He was treated as pulmonary tuberculosis (PTB) but had gross haematuria a month after initiation of anti-tubercular drugs (ATD). He was investigated with computed tomography (CT) imaging and was found to have thickened renal pelvis and ureter. It was initially thought as a case of genito-urinary tuberculosis (GUTB). Expectant management for gross haematuria failed. The patient was stabilised and taken up for open nephroureterectomy under general anaesthesia (GA). Histopathological report suggested it to be high grade TCC of the left renal pelvis extending to upper ureter. He did well with completion of ATD. He was not started on adjuvant chemotherapy for fear of exacerbation of PTB. He is under regular and uneventful follow up in the outpatient department (OPD).

Download Full-text